By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced on September 7, 2026 that SHR‑1179 has been approved by China’s National Medical Products Administration (NMPA) for clinical trials in weight management.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) |
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval (IND) |
| Product | SHR‑1179 |
| Classification | Class 1 therapeutic biological product — independently developed |
| Indication | Weight management |
| Approval Date | 7 Sep 2026 |
| First‑in‑Class Status | No drugs targeting the same mechanism approved for market launch in China or abroad |
Product Profile
- Modality: Class 1 therapeutic biological product (China’s highest novelty classification for biologics), independently developed by Hengrui
- Target Indication: Weight management
- Differentiation: SHR‑1179 pursues a mechanism for which no approved drug currently exists globally, positioning it as a potential first‑in‑class entrant in the weight management space
Market Impact & Outlook
- Beyond the Incretin Wave: The global weight management market is currently dominated by GLP‑1–based therapies. A novel‑mechanism biologic with no approved competitor worldwide would give Hengrui a differentiated position should SHR‑1179 demonstrate efficacy in upcoming trials.
- China’s Obesity Market: With rising obesity prevalence and rapidly expanding metabolic disease treatment demand, China represents one of the largest long‑term opportunities in weight management therapeutics.
- Pipeline Momentum for Hengrui: The IND clearance adds another first‑in‑class biological asset to Hengrui’s portfolio, reinforcing the company’s shift toward globally competitive innovative drugs.
- Next Catalysts: Clinical trial initiation and early safety, tolerability, and proof‑of‑concept data will be the key readouts determining SHR‑1179’s first‑in‑class potential.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial conduct, mechanism validation, and future regulatory approval of SHR‑1179. Actual results may differ due to risks including trial outcomes, regulatory timelines, market adoption, and competitive dynamics.-Fineline Info & Tech